MHRA: Marketing Authorisation Variation Application 2025 Rules Updated

• UK marketing authorisation types, including UK-wide and NI-only, were redefined from January 1, 2025.
• Centralised marketing authorisations and their variations ceased to be valid in Northern Ireland as of January 1, 2025.
• Commission Regulation 2024/1701, amending the EU Variations Regulation, became applicable in the UK from January 1, 2025.
• New European Commission guidance on variation categories and procedures, Communication 2025/5045, will apply from January 15, 2026.
• The application process for marketing authorisation variations in the UK from January 1, 2025, depends on the specific marketing authorisation type and the lead regulatory authority.

The evolving regulatory landscape, with significant changes taking effect from January 1, 2025, and further guidance from January 15, 2026, necessitates a thorough understanding for all marketing authorisation holders.

Significant changes to the types of marketing authorisations (MAs) available in the United Kingdom came into effect on January 1, 2025. From this date, products can be authorised for sale and supply across the entire UK under a purely national UK-wide MA, irrespective of the application route, which could include direct national, International Recognition Procedure (IRP), Project Orbis, or Access pathways.

Additionally, UK-wide MAs that were initially granted as part of a Mutual Recognition/Decentralised (MR/DC) procedure with the UK as a Concerned Member State (CMS) before January 1, 2021, retain the option for the MA holder to continue managing them in line with the MR/DC procedure, with Northern Ireland (NI) remaining as a CMS. It is important to note that new UK-wide MAs can no longer be sought through EU procedures. For Northern Ireland specifically, NI Only MAs (PLNI) are available, authorising products solely for sale and supply within NI as part of an MR/DC procedure where NI is the sole concerned member state.

Furthermore, as of January 1, 2025, centralised marketing authorisations and any subsequent variations to them ceased to be valid within Northern Ireland. These structural shifts in UK marketing authorisation types 2025 fundamentally alter the regulatory environment for pharmaceutical products across the nation.

The legal framework governing variations to marketing authorisations in the UK has a direct lineage from European Union regulations. Specifically, Chapter IIa of the EU Variations Regulation (EC) No 1234/2008, which addresses variations to national marketing authorisations for medicinal products for human use within the EU, was incorporated into UK law on December 31, 2020. These provisions continue to apply to purely national UK marketing authorisations, as stipulated in Regulation 65C and Schedule 10A to the Human Medicines Regulations 2012, as amended.

A further significant update to this framework is the implementation of Commission Regulation 2024/1701. This regulation, dated March 11, 2024, amends the original Variations Regulation (EC) No 1234/2008. It entered into force on July 7, 2024, and became applicable in the UK from January 1, 2025, directly impacting the MHRA marketing authorisation variation application 2025 process and the broader landscape of medicines marketing authorisation changes.

Variations to marketing authorisations are broadly categorised based on their nature and potential impact. These can include administrative changes, such as alterations to a company's name or address; changes affecting a product's characteristics, like its composition, manufacturing method, or testing procedures; or modifications that could influence the product's safety, efficacy, or pharmacovigilance requirements. These changes are further classified as either minor (Type IA or IB) or major (Type II).

Following the revision of the Variations Regulation, the European Commission (EC) issued Communication 2025/5045 on September 22, 2025. This communication provides comprehensive guidance on the various categories of variations and outlines the operational procedures for their submission and assessment. This new MHRA variation guidance 2026 is set to become applicable from January 15, 2026.

From January 1, 2025, the specific application procedure for different types of UK marketing authorisations will be determined by the regulatory authority responsible for leading the assessment, reflecting the nuanced regulatory environment for medicines marketing authorisation changes.

The evolving regulatory landscape, with significant changes taking effect from January 1, 2025, and further guidance from January 15, 2026, necessitates a thorough understanding for all marketing authorisation holders. The redefinition of UK marketing authorisation types 2025, including the distinction between UK-wide and NI-only MAs, directly influences how variation applications are submitted and processed.

Compliance with the updated Human Medicines Regulations 2012 amendments, particularly in light of Commission Regulation 2024/1701, is crucial for any MHRA marketing authorisation variation application 2025. Companies must assess their existing authorisations and future variation strategies against these new requirements to ensure continued adherence and efficient management of their medicinal products.

Lawyers and compliance officers must review the new regulations and guidance for marketing authorisation variations in the UK, effective from January 2025 and January 2026, to ensure their clients' or companies' applications comply with updated requirements and to understand the implications for UK-wide versus NI-only MAs.

Source: Original reporting via GOV.UK